Accumulating evidence has made everolimus approved for the treatment of metastatic ER positive, HER2 negative BC patients, because everolimus could effectively restrain the proliferation via inhibiting serine/ threonine kinase mTOR 2, 27. The gene discussed is MARK2; the disease is breast cancer.